INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 50 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $10,935,000 | -18.9% | 13,500,000 | -25.0% | 0.38% | -41.9% |
Q2 2020 | $13,479,000 | -8.5% | 18,000,000 | 0.0% | 0.65% | -37.6% |
Q1 2020 | $14,732,000 | -9.1% | 18,000,000 | +12.5% | 1.04% | +76.0% |
Q4 2019 | $16,205,000 | +17.6% | 16,000,000 | 0.0% | 0.59% | +31.3% |
Q3 2019 | $13,775,000 | -4.5% | 16,000,000 | 0.0% | 0.45% | +6.1% |
Q2 2019 | $14,420,000 | +21.2% | 16,000,000 | +33.3% | 0.42% | -33.6% |
Q1 2019 | $11,895,000 | -11.9% | 12,000,000 | -18.0% | 0.64% | +7.4% |
Q4 2018 | $13,509,000 | -8.5% | 14,636,000 | 0.0% | 0.60% | +93.8% |
Q3 2018 | $14,768,000 | +23.6% | 14,636,000 | +7.3% | 0.31% | -31.0% |
Q2 2018 | $11,946,000 | -42.6% | 13,636,000 | -47.4% | 0.44% | -20.0% |
Q1 2018 | $20,796,000 | +101.0% | 25,912,000 | +100.0% | 0.56% | +105.9% |
Q4 2017 | $10,348,000 | – | 12,956,000 | – | 0.27% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Man Investments (CH) AG | 3,300,000 | $2,640,000 | 2.48% |
SYMPHONY ASSET MANAGEMENT LLC | 14,000,000 | $11,200,000 | 1.14% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 36,000,000 | $28,879,000 | 1.14% |
Opera Trading Capital | 5,500,000 | $4,344,000 | 0.89% |
MACKAY SHIELDS LLC | 17,789,000 | $14,221,000 | 0.52% |
TENOR CAPITAL MANAGEMENT Co., L.P. | 6,000,000 | $4,918,000 | 0.37% |
ADVENT CAPITAL MANAGEMENT /DE/ | 24,415,000 | $19,539,000 | 0.37% |
OAKTREE CAPITAL MANAGEMENT LP | 28,415,000 | $22,732,000 | 0.36% |
GLG Partners LP | 8,700,000 | $6,960,000 | 0.33% |
HIGHFIELDS CAPITAL MANAGEMENT LP | 42,285,000 | $33,828,000 | 0.28% |